Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 09 - 05 symbols : SNYNF save search
Global Treatment Resistant Depression Market to Surpass US$ 1,545.6 Million by 2030 - Coherent Market Insights
Published: 2022-09-05 (Crawled : 19:00) - prnewswire.com
GLAXF | $20.2 0.65% -14.18% 290
|
Health Technology
|
| O: 0.6%
H: 0.0%
C: -4.59%
SNYNF | News | $92.7 0.63% -2.18% 1.4K
|
Health Technology
|
| O: -2.93%
H: 10.14%
C: 3.79%
ATAI | News | $1.98 -7.91% -8.59% 1.4M
|
Manufacturing
|
| O: 1.61%
H: 0.45%
C: -4.97%
VTRS | $11.1 -0.18% -0.23% 4.7M
|
Health Technology
|
| O: 0.42%
H: 0.0%
C: -0.84%
JNJ | News | $144.77 0.22% 0.22% 7.9M
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
GSK | $39.6 -0.88% 0.03% 2.6M
|
Health Technology
|
| O: -0.63%
H: 0.35%
C: -0.57%
LLY | News | $750.77 0.54% 0.22% 2.8M
|
Health Technology
|
| O: 0.54%
H: 3.26%
C: 1.28%
BHC | $8.66 -0.92% -0.58% 2.2M
|
Health Technology
|
| O: 0.47%
H: 1.39%
C: 0.15%
ABBV | $164.25 1.05% 0.26% 3M
|
Health Technology
|
| O: 0.75%
H: 1.49%
C: 0.21%
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
|
| O: -1.35%
H: 0.0%
C: 0.0%
treatment global depression market
Global Osteoarthritis Drugs Market to surpass US$ 16,184.9 million by 2030 - Coherent Market Insights
Published: 2022-09-05 (Crawled : 18:00) - prnewswire.com
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
| Email alert
Add to watchlist
GSK | $39.6 -0.88% 0.03% 2.6M
|
Health Technology
| Email alert
Add to watchlist
RDUS | $18.22 4.53% 4.28% 270K
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $144.77 0.22% 0.22% 7.9M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 0.63% -2.18% 1.4K
|
Health Technology
| Email alert
Add to watchlist
NVS | News | $93.08 -0.13% 0.13% 1.1M
|
Health Technology
| Email alert
Add to watchlist
GLAXF | $20.2 0.65% -14.18% 290
|
Health Technology
| Email alert
Add to watchlist
LLY | News | $750.77 0.54% 0.22% 2.8M
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
| Email alert
Add to watchlist
AVNS | $18.71 0.32% 0.0% 310K
|
Health Technology
| Email alert
Add to watchlist
PFE A | $25.42 -1.05% 0.16% 40M
|
Health Technology
| Email alert
Add to watchlist
osteoarthritis global market
Vitiligo Treatment Market Size Worth US$ 2.42 Billion With CAGR of 6.14% from 2022 to 2030 | Exclusive Report by Growth Plus Reports
Published: 2022-09-05 (Crawled : 14:00) - prnewswire.com
GLAXF | $20.2 0.65% -14.18% 290
|
Health Technology
| Email alert
Add to watchlist
ALPMF | News | $9.594 1.2% 43.47% 0
|
Health Technology
| Email alert
Add to watchlist
INCY | $52.72 -0.94% -0.91% 2.1M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 0.63% -2.18% 1.4K
|
Health Technology
| Email alert
Add to watchlist
ALPMY | News | $9.46 1.29% -1.11% 500K
|
Manufacturing
| Email alert
Add to watchlist
GSK | $39.6 -0.88% 0.03% 2.6M
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
| Email alert
Add to watchlist
ABBV | $164.25 1.05% 0.26% 3M
|
Health Technology
| Email alert
Add to watchlist
LLY | News | $750.77 0.54% 0.22% 2.8M
|
Health Technology
| Email alert
Add to watchlist
treatment report plus growth market
Late-Breaking Dupixent® (dupilumab) Data at ERS 2022 Show Consistent Efficacy and Safety Profile for Up to Two Years in Children Aged 6 to 11 Years with Moderate-to-severe Asthma
Published: 2022-09-05 (Crawled : 12:00) - prnewswire.com
TEVJF | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
REGN | $901.19 0.79% 0.78% 320K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 0.63% -2.18% 1.4K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
| Email alert
Add to watchlist
dupixent children
Outlook on the Hereditary Angioedema Global Market to 2030 - Size, Share, Outlook, and Opportunity Analysis
Published: 2022-09-05 (Crawled : 11:00) - prnewswire.com
CNTG | $0.48 -0.02% 0.14% 17K
|
Commercial Services
| Email alert
Add to watchlist
ADVM | $11.35 -2.24% -2.56% 68K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 0.63% -2.18% 1.4K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
| Email alert
Add to watchlist
IONS | $40.91 -1.52% -1.49% 1.2M
|
Health Technology
| Email alert
Add to watchlist
BCRX | News | $4.58 -0.65% -0.44% 3.3M
|
Health Technology
| Email alert
Add to watchlist
ARWR | $22.53 -4.82% -5.11% 860K
|
Health Technology
| Email alert
Add to watchlist
TAK | $13.15 -0.61% 0.0% 1.5M
|
Health Technology
| Email alert
Add to watchlist
global market hereditary angioedema
Innate Pharma to Present Lacutamab PTCL Phase 1b Design and ANKET™ Platform at ESMO 2022
Published: 2022-09-05 (Crawled : 08:00) - biospace.com/
IPHA | $2.41 -6.95% -10.21% 16K
|
Health Technology
| Email alert
Add to watchlist
NVO | News | $124.53 0.88% 0.19% 2.5M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 0.63% -2.18% 1.4K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
| Email alert
Add to watchlist
IPHYF | $2.65 104.6% 300
|
Health Technology
| Email alert
Add to watchlist
pharma platform phase 2b
Press Release: Evolution of the Board of Directors
Published: 2022-09-05 (Crawled : 06:00) - globenewswire.com
SNYNF | News | $92.7 0.63% -2.18% 1.4K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
| Email alert
Add to watchlist
Press Release: Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children aged 6 to 11 years with moderate-to-severe asthma
Published: 2022-09-05 (Crawled : 06:00) - globenewswire.com
TEVJF | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 0.63% -2.18% 1.4K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
| Email alert
Add to watchlist
REGN | $901.19 0.79% 0.78% 320K
|
Health Technology
| Email alert
Add to watchlist
dupixent children
FDA Review: Immusoft, BioCryst, Intellia and More
Published: 2022-09-05 (Crawled : 05:00) - biospace.com/
SNYNF | News | $92.7 0.63% -2.18% 1.4K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
| Email alert
Add to watchlist
fda
Innovent Announces First Participant Dosed in the Higher-dose Cohort of a Phase 2 Clinical Trial of Mazdutide in Chinese Adults with Obesity
Published: 2022-09-05 (Crawled : 01:00) - prnewswire.com
LLY | News | $750.77 0.54% 0.22% 2.8M
|
Health Technology
| Email alert
Add to watchlist
INCY | $52.72 -0.94% -0.91% 2.1M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 0.63% -2.18% 1.4K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
| Email alert
Add to watchlist
obesity chinese trial phase 2
Gainers vs Losers
| 57% | 43% |
Top 10 Gainers
INVO | $1.82 139.47% 56.82% 220M
|
Health Technology
SINT | $0.0373 62.88% 37.26% 460M
|
Health Technology
WISA 4 | $9.25 51.64% 34.27% 64M
|
Electronic Technology
EDBL | News | $6.66 46.37% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 600K
|
Manufacturing
TCON | $2.29 33.92% 26.61% 1.8M
|
Health Technology
TIRX | $0.4848 7.49% 24.58% 5.9M
|
SRFM 4 | $0.3859 -12.3% 23.84% 660K
|
n/a
KZIA | $0.3442 18.28% 23.42% 290K
|
Health Technology
CTM | $0.2201 -2.31% 22.67% 48K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.